Preliminary results from Russian trials find that vaccine candidates led to no serious adverse events and elicit antibody response

Results from two early-phase Russian non-randomised vaccine trials (Sputnik V) in a total of 76 people are published today in The Lancet, finding that two formulations of a two-part vaccine have a good safety profile with no serious adverse events detected over 42 days, and induce antibody responses in all participants within 21 days.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news